Home-Logo
left-arrow
person

A/Prof. David Groth

Associate Professor
Diagnostic and Therapeutic Sciences

Molecular Geneticist . Joint Program Lead in Molecular Neurosciences

My interest in this field was first sparked in 1999 when I met Professor Ralph Martins at a function showcasing his students’ honours presentations. This encounter inspired me to undertake a sabbatical with Professor Martins at Edith Cowan University and Macquarie University, where I developed lasting professional relationships and friendships with his former students, Associate Professor Giuseppe Verdile and Professor Simon Laws. Together, we achieved a significant milestone by successfully expressing a functional gamma-secretase complex in insect cells.


About

Currently, Associate Professor Groth serves as Joint Program Lead in Molecular Neuroscience at the Curtin Medical Research Institute (Curtin MRI). His long-term research interests focus on understanding the structure and potential mechanisms of action of Alzheimer’s disease-related gamma secretases, fostering enduring collaborations in this field.

In addition to his research leadership, Associate Professor Groth holds several prestigious professional roles. He is Chair of the Scientific Advisory Committee and a Board Member of the McCusker Research Foundation for Alzheimer’s Disease. He also serves as Chair of the Institutional Biosafety Committee at Curtin University, and is an active member of multiple international scientific organisations, including the American Association for the Advancement of Science, the International Forensic Genetic Society, the Genetic Society (UK), the Genetic Society of America, and the International Society of Animal Genetics.

 
  • Chair of Scientific Advisory Committee McCusker Research Foundation for Alzheimer's Disease
  • Member of the Board of the McCusker Research Foundation for Alzheimer's Disease
  • Chair of the Institutional Biosafety Committee (Curtin University)
  • Member of the American Society for the Advancement of Science
  • Member of the International Forensic Genetic Society
  • Member of Genetic Society (UK)
  • Member of Genetic Society of America
  • Member of International Society of Animal Genetics

A/Prof David Groth's  research can be divided into four main areas;

Population genetics

Currently, I am supervising students involving in molecular genetics projects on the Noisy Scub Bird and the Western Swamp Tortoise.

The aims of this research are:

  • Development and use of molecular tools for the analysis of population genetics in these endangered species.
  • Use of next generation sequencing to discover microsatellites to assist in the above aim.

Understanding the sheep major histocompatibility complex and other regions of the sheep genome and their role in sheep parasitic diseases.

The aims of this research are:

  •  To develop a single nucleotide polymorphism map of the sheep MHC.
  •  Apply SNPs to identifying genes involved with IgA and IgE responses to gastrointestinal parasites.
  •  Use the information gained as a model for human IgE responses and systems involved in parasite responses.
  • Comparative analysis of the MHC

The role of Corneodesmosin and other related desmosomal proteins in skin and hair/wool structure and their role in skin diseases and wool production traits

Aims of this research are:

  • Understand the effects of variation in corneodesmosin and other proteins found in the corneodesmosome on their structure and function.
  • Understand the possible role of Corneodesmosin and other related proteins in the pathogenesis of human skin diseases such as psoriasis.

The molecular mechanisms of Alzheimer’s disease.  This work is in collaboration with Professor Ralph Martins from ECU. The research involves the construction of recombinant Baculoviral constructs and their use in determining the minimal gamma secretase complex required for amyloid-beta production.  

EMAIL: D.Groth@curtin.edu.au
TEL: 
+61 (08) 9266 2342
Curtin Staff Profile

Research Focus

As a Molecular Geneticist and Joint Program Lead in Molecular Neuroscience at the Curtin Medical Research Institute (Curtin MRI), my research focuses on uncovering the molecular mechanisms underlying Alzheimer’s disease and exploring the genetics of immune, stress, and adaptive responses across species.

My principal work investigates the structure and function of the Alzheimer’s disease-related gamma-secretase complex using insect cell (baculovirus) and zebrafish expression systems. In collaboration with Professor Ralph Martins (ECU & Macquarie University) and his colleagues, we successfully expressed a functional gamma-secretase complex in insect cells, contributing to a deeper understanding of amyloid-beta production.

A complementary research stream examines how stress and the hypothalamic–pituitary–adrenal (HPA) axis influence Alzheimer’s disease progression. This work highlights genetic variations in HPA-related genes that may accelerate disease development, shedding light on the interaction between stress and neuroinflammation. Beyond neuroscience, my broader research spans population genetics, immunogenetics, and skin biology. Current projects include developing molecular tools for the conservation genetics of endangered species, mapping immune related genes in sheep to understand parasite resistance, and investigating desmosomal proteins involved in skin and wool structure and human skin diseases such as psoriasis.

I also maintain a long-standing interest in the sheep major histocompatibility complex (MHC), where next-generation sequencing has revealed over 4,000 SNPs. These findings enhance our understanding of evolutionary genetics and the molecular basis of host–parasite interactions.

Research Team

A/Prof. Giuseppe Verdile

Associate Professor

Amy O'Keefe

PhD Student

Cate Ayers

Honours Student

Publications

ABSTRACT:

The sheep major histocompatibility complex (Mhc) was first identified 15 years ago by serological studies of sheep lymphocyte antigens. 1 Since then both classical class I and class II molecules have been identified as membrane-associated molecules (antigens) on sheep peripheral blood lymphocytes by serological and immunochemical methods. The relative paucity of international resources has meant that serological characterization of the sheep Mhc has been slow. In recent years the emphasis has moved to the use of the molecular techniques to characterize the ovine Mhc region. Relative to other domesticated species the ovine Mhc is poorly characterized. To date the class II region has been the focus for most investigations while the class I region has received little attention since the early flurry of serological effort. The presence of a class III region is still imputed by analogy with other ungulate species.

The sheep Mhc was initially termed OLA (ovine lymphocyte antigens) and is still referred to occasionally by this name, as a reflection of its serological history. However, to strengthen efforts for a systematic nomenclature of the Mhc in all vertebrates, 2 the sheep Mhc will be referred to as Ovar (from Ov is aries) in this chapter. The ovine Mhc has been mapped to chromosome 20q15-q23. 3 , 4 Although no overall physical map exists so far, information from overlapping cosmids and linkage analysis studies indicate similarities of the Ovar complex to cattle and human 5 , 6 (Groth and Wetherall, unpublished data; Crawford et al., unpublished data).

Schwaiger, F. W., J. Maddox, K. Ballingall, J. Buitkamp, A. M. Crawford, B. M. Dutia, J. T. Epplen, E. D. Ferguson, D. Groth, J. Hopkins, and 4 more contributors. 2026. The Ovine Major Histocompatibility Complex." In Major Histocompatibility Complex Region of Domestic Animal Species, 121-176
ABSTRACT:

Rigid spine syndrome is a rare childhood-onset myopathy characterized by slowly progressive or non-progressive scoliosis, neck and spine contractures, hypotonia and respiratory insufficiency. Biallelic variants in SELENON account for most cases of rigid spine syndrome, however, the underlying genetic cause in some patients remains unexplained. We used exome and genome sequencing to investigate the genetic basis of rigid spine syndrome in patients without a genetic diagnosis.

In five patients from four unrelated families, we identified biallelic variants in HMGCS1 (3-hydroxy-3-methylglutaryl-coenzyme A synthase). These included six missense variants and one frameshift variant distributed throughout HMGCS1. All patients presented with spinal rigidity primarily affecting the cervical and dorso-lumbar regions, scoliosis and respiratory insufficiency. Creatine kinase levels were variably elevated. The clinical course worsened with intercurrent disease or certain drugs in some patients; one patient died from respiratory failure following infection. Muscle biopsies revealed irregularities in oxidative enzyme staining with occasional internal nuclei and rimmed vacuoles.

HMGCS1 encodes a critical enzyme of the mevalonate pathway and has not yet been associated with disease. Notably, biallelic hypomorphic variants in downstream enzymes including HMGCR and GGPS1 are associated with muscular dystrophy resembling our cohort’s presentation. Analyses of recombinant human HMGCS1 protein and four variants (p.S447P, p.Q29L, p.M70T, p.C268S) showed that all mutants maintained their dimerization state. Three of the four mutants exhibited reduced thermal stability, and two mutants showed subtle changes in enzymatic activity compared to the wildtype.

Hmgcs1 mutant zebrafish displayed severe early defects, including immobility at 2 days and death by Day 3 post-fertilisation and were rescued by HMGCS1 mRNA. We demonstrate that the four variants tested (S447P, Q29L, M70T and C268S) have reduced function compared to wild-type HMGCS1 in zebrafish rescue assays. Additionally, we demonstrate the potential for mevalonic acid supplementation to reduce phenotypic severity in mutant zebrafish. Overall, our analyses suggest that these missense variants in HMGCS1 act through a hypomorphic mechanism.

Here, we report an additional component of the mevalonate pathway associated with disease and suggest biallelic variants in HMGCS1 should be considered in patients presenting with an unresolved rigid spine myopathy phenotype. Additionally, we highlight mevalonoic acid supplementation as a potential treatment for patients with HMGCS1-related disease.

Dofash, L. N. H., L. B. Miles, Y. Saito, E. Rivas, V. Calcinotto, S. Oveissi, R. J. Serrano, R. Templin, G. Ramm, A. Rodger, and 31 more contributors. 2025. HMGCS1 variants cause rigid spine syndrome amenable to mevalonic acid treatment in an animal model. Brain 148 (5): 1707-1722.

Find a researcher

Search for researchers at Curtin MRI

Search by name

Search by area of research